NEWS , Press release
2025.9.10
Strategic Alliance Agreement with Eutilex (Korea) on the Development of Next-Generation Allogeneic CAR-T Therapies Derived from iPS Cells
Rebirthel and Eutilex announce that they have entered into a contract on entered into a Strategic Alliance Agreement on the Development of Next-Generation Allogeneic CAR-T Therapies Derived from iPS Cells.
Eutilex is one of the leading biotech companies in South Korea, focused on immuno-oncology therapeutics.
For details, please refer to the attached press release.
Strategic Alliance Agreement with Eutilex on the Development of Next-Generation Allogeneic CAR-T Therapies Derived from iPS Cellsダウンロード
(From left to right) Kawamoto Hiroshi, CTO of Rebirthel; Yoo Yeonho, CEO of Eutilex; Kajikawa Masunori, CEO of Rebirthel